Medicine and Dentistry
Neoplasm
48%
Vestibular Schwannoma
44%
Magnetic Resonance Imaging
35%
Dynamic Contrast-Enhanced MRI
23%
Neurofibromatosis Type II
22%
Biological Marker
21%
Contrast Medium
19%
Low Drug Dose
18%
Brain Tumor
15%
Antiangiogenic Therapy
13%
Perfusion Weighted Imaging
13%
Dynamic Susceptibility Contrast
13%
Treatment Response
10%
Gadolinium
9%
Glioblastoma
9%
Angiogenesis
9%
Radiosurgery
8%
Diffusion MRI
8%
Brain Blood Flow
8%
Blood Vessel Permeability
7%
Stereotactic Radiosurgery
7%
Tumor
7%
Magnetic Resonance Imaging
6%
Breast Cancer
6%
Recurrent Disease
6%
PK-11195
6%
Brain Perfusion
6%
Microsphere
6%
Scintigraphy
6%
Chemoradiotherapy
6%
Cediranib
6%
Rectum Cancer
6%
Multinuclear Magnetic Resonance Imaging
6%
Moyamoya Disease
6%
Phase I Trials
6%
Radiation Therapy
6%
Intracranial Tumor
6%
Imaging Technique
6%
Gadolinium
6%
Bevacizumab
5%
Blood Flow
5%
Neuroscience
Magnetic Resonance Imaging
100%
Brain Tumor
40%
Contrast Medium
36%
Acoustic Neuroma
25%
T2 Contrast
13%
Meningioma
13%
Pharmacokinetics
13%
Neurofibromatosis Type II
10%
Schwannoma
9%
In Vivo
8%
Diffusion MRI
8%
Arterial Spin Labeling
8%
Magnetic Resonance Imaging
6%
Microsphere
6%
Perfusion Magnetic Resonance Imaging
6%
VEGF Receptors
6%
Receptor Tyrosine Kinase Inhibitors
6%
Thymostimulin
6%
Blood Brain Barrier
6%
Superior Sagittal Sinus
6%
Dynamic Susceptibility Contrast
6%
Multinuclear Magnetic Resonance Imaging
6%
Brain Tumor
6%
Behavior (Neuroscience)
6%
Microvessel
6%
Blood Vessel Permeability
6%
Bevacizumab
5%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
22%
Neurofibromatosis Type 2
20%
Acoustic Neuroma
17%
Breast Cancer
13%
Pentetic Acid
11%
Contrast Medium
10%
Pharmacokinetic Parameter
8%
Protein Tyrosine Kinase Inhibitor
7%
Gadolinium
7%
Recurrent Disease
6%
Rectum Cancer
6%
Vasculotropin Receptor
6%
Protein Tyrosine Kinase
6%
Moyamoya Disease
6%
Glioma
6%
Phase I Trials
6%
Microsphere
6%
Intracranial Tumor
6%
Cediranib
6%
Brain Tumor
6%
Glioblastoma
5%
